Flexion Therapeutics Inc (NASDAQ:FLXN) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 1,086 call options on the stock. This represents an increase of approximately 1,310% compared to the average daily volume of 77 call options.
In related news, CEO Michael D. Clayman acquired 10,000 shares of the stock in a transaction on Thursday, August 9th. The stock was purchased at an average price of $22.33 per share, for a total transaction of $223,300.00. Following the transaction, the chief executive officer now owns 75,282 shares of the company’s stock, valued at approximately $1,681,047.06. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Neil Bodick sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $25.07, for a total transaction of $1,253,500.00. The disclosure for this sale can be found here. Company insiders own 14.59% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of FLXN. Redmile Group LLC acquired a new position in Flexion Therapeutics during the first quarter valued at approximately $223,000. Stifel Financial Corp acquired a new position in Flexion Therapeutics during the first quarter valued at approximately $293,000. Cubist Systematic Strategies LLC acquired a new position in Flexion Therapeutics during the first quarter valued at approximately $381,000. Wexford Capital LP acquired a new position in Flexion Therapeutics during the first quarter valued at approximately $401,000. Finally, State Board of Administration of Florida Retirement System grew its holdings in Flexion Therapeutics by 22.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock valued at $411,000 after purchasing an additional 2,960 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.06. The firm had revenue of $3.80 million for the quarter, compared to analyst estimates of $3.96 million. equities research analysts predict that Flexion Therapeutics will post -4.75 earnings per share for the current year.
Several equities research analysts have recently commented on the stock. ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. BidaskClub cut shares of Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 20th. Zacks Investment Research cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Finally, Benchmark assumed coverage on shares of Flexion Therapeutics in a research report on Thursday, June 28th. They set a “buy” rating and a $39.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $91.50.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Read More: Market Capitalization
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.